The specialty pharmaceutical company Pharmalink AB today announced that it has changed its name to Calliditas Therapeutics AB (“Calliditas Therapeutics” or the “company”).
The Swedish Companies Registration Office has approved and registered the company’s change of name from Pharmalink AB to Calliditas Therapeutics AB. More information about Calliditas Therapeutics and its clinical projects can be found on the new website www.calliditas.se.
For further information, please contact:
Calliditas Therapeutics AB
Renée Aguiar-Lucander, Chief Executive Officer
Mobile: +46 (0)72 252 1006
Email: renee.lucander@calliditas.se
Mikael Widell, Head of Communications
Mobile: +46 (0)70 311 9960
Email: mikael.widell@calliditas.se
www.calliditas.se
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Hollie Vile
Email: calliditas@optimumcomms.com
Tel: +44 (0)203 714 1787
Notes to editors
About Calliditas Therapeutics
Calliditas Therapeutics is a specialty pharmaceutical company focused on developing high value medical products for patients with significant unmet medical needs in niche indications. Calliditas Therapeutics is focused on the development and commercialization of its lead product candidate, Nefecon, which has successfully completed a Phase 2b clinical study as a potential new treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Backed by a strong investor base with a clear long-term vision and a track record of bringing products to the market, Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. In addition, the company has identified other potential uses of Nefecon in niche indications, and will investigate the development of these to provide new treatments for patients with unmet medical needs.
Visit www.calliditas.se for further information.